A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia

CK2 Phosphorylating I2PP2A/SET Mediates Tau Pathology and Cognitive Impairment

(2018) Qing Zhang et al.   Frontiers in Molecular Neuroscience

Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back

(2018) Jukka Westermarck   FEBS Journal

The split protein phosphatase system

(2018) Anne Bertolotti   BIOCHEMICAL JOURNAL

Zebrafish: Speeding Up the Cancer Drug Discovery Process

(2018) Patricia Letrado et al.   CANCER RESEARCH

Therapeutic targeting of CK2 in acute and chronic leukemias

(2017) F Buontempo et al.   LEUKEMIA

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Zebrafish larvae could help to personalize cancer treatments

(2017) Mitch Leslie   SCIENCE

Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies

(2017) Rocio Acuna-Hidalgo et al.   PLoS Genetics

Oxidative stress disassembles the p38/NPM/PP2A complex, which leads to modulation of nucleophosmin-mediated signaling to DNA damage response

(2016) Maëva Guillonneau et al.   FASEB JOURNAL

MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia

(2016) Raffaella Pippa et al.   Oncotarget

Protein Phosphatase 2A as a Therapeutic Target in Acute Myeloid Leukemia

(2016) Elena Arriazu et al.   Frontiers in Oncology

Emerging therapeutic drugs for AML

(2015) E. M. Stein et al.   BLOOD

The Stress Kinase p38  as a Target for Cancer Therapy

(2015) A. Igea et al.   CANCER RESEARCH

Lipid Nanosystems Enhance the Bioavailability and the Therapeutic Efficacy of FTY720 in Acute Myeloid Leukemia

(2015) A. Estella-Hermoso de Mendoza et al.   Journal of Biomedical Nanotechnology

Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia

(2015) Steven M Chan et al.   NATURE MEDICINE

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Nuclear Oncogene SET Controls DNA Repair by KAP1 and HP1 Retention to Chromatin

(2015) Alkmini Kalousi et al.   Cell Reports

Activation of the MAPK11/12/13/14 (p38 MAPK) pathway regulates the transcription of autophagy genes in response to oxidative stress induced by a novel copper complex in HeLa cells

(2014) Wu Zhong et al.   Autophagy

Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia

(2014) A. Agarwal et al.   CLINICAL CANCER RESEARCH

Inhibition of FoxO1 acetylation by INHAT subunit SET/TAF-Iβ induces p21 transcription

(2014) Yun-Cheol Chae et al.   FEBS LETTERS

The p38β Mitogen-activated Protein Kinase Possesses an Intrinsic Autophosphorylation Activity, Generated by a Short Region Composed of the α-G Helix and MAPK Insert

(2014) Jonah Beenstock et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of FTY720 on the SET–PP2A complex in acute myeloid leukemia; SET binding drugs have antagonistic activity

(2014) R Pippa et al.   LEUKEMIA

The PP2A Inhibitor I2PP2A Is Essential for Sister Chromatid Segregation in Oocyte Meiosis II

(2013) Jean-Philippe Chambon et al.   CURRENT BIOLOGY

Acute myeloid leukaemia in adults

(2013) Felicetto Ferrara et al.   LANCET

Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease

(2013) Guang Yu et al.   NEUROBIOLOGY OF AGING

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

(2012) Rocco Piazza et al.   NATURE GENETICS

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

Survival of Cancer Stem Cells under Hypoxia and Serum Depletion via Decrease in PP2A Activity and Activation of p38-MAPKAPK2-Hsp27

(2012) Shih-Pei Lin et al.   PLoS One

Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET

(2011) Lisette Arnaud et al.   FEBS LETTERS

Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia

(2011) I. Cristobal et al.   HAEMATOLOGICA

PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect

(2011) I Cristóbal et al.   LEUKEMIA

Genetic analysis of specific and redundant roles for p38  and p38  MAPKs during mouse development

(2011) I. del Barco Barrantes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural Bioinformatics-Based Prediction of Exceptional Selectivity of p38 MAP Kinase Inhibitor PH-797804

(2009) Li Xing et al.   BIOCHEMISTRY

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML

(2009) K. W. Pratz et al.   BLOOD

SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia

(2009) I. Cristobal et al.   BLOOD

Phosphatase-mediated crosstalk between MAPK signaling pathways in the regulation of cell survival

(2007) Melissa R. Junttila et al.   FASEB JOURNAL